COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study

被引：4

作者：

Erden, A. ^{[1
,2
]}

Karakas, O. ^{[1
,2
]}

Armagan, B. ^{[1
,2
]}

Guven, S. C. ^{[1
,2
]}

Ozdemir, B. ^{[1
,2
]}

Atalar, E. ^{[1
,2
]}

Apaydin, H. ^{[1
,2
]}

Usul, E. ^{[1
,3
]}

Ates, I ^{[1
,4
]}

Omma, A. ^{[1
,2
]}

Kucuksahin, O. ^{[1
,5
]}

机构：

[1] Ankara Sehir Hastanesi, MH6 Onkol Binasi, Romatol Bolumu, TR-06800 Ankara, Turkey

[2] Minist Hlth, Clin Rheumatol, Ankara City Hosp, Ankara, Turkey

[3] Sincan Dr Nafiz Korez State Hosp, Clin Emergency Med, Ankara, Turkey

[4] Univ Hlth Sci, Minist Hlth, Sch Med, Dept Internal Med,Ankara City Hosp, Ankara, Turkey

[5] Ankara Yildirim Bayezit Univ, Sch Med, Dept Internal Med, Div Rheumatol, Ankara, Turkey

来源：

BRATISLAVA MEDICAL JOURNAL | 2022年 / 123卷 / 02期

关键词：

antiphospholipid syndrome; COVID-19; outcome; thrombosis; mortality; INTERNATIONAL CONSENSUS STATEMENT; CLASSIFICATION CRITERIA; MECHANISMS;

D O I：

10.4149/BLL_2022_018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR-positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33). Text in PDF www.elis.sk

引用

页码：120 / 124

页数：5

共 34 条

[1] Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis [J].

Akiyama, Shintaro ;

Hamdeh, Shadi ;

Micic, Dejan ;

Sakuraba, Atsushi .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (03) :384-391

[2] Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-β2Glycoprotein I Antibodies [J].

Andreoli, Laura ;

Fredi, Micaela ;

Nalli, Cecilia ;

Piantoni, Silvia ;

Reggia, Rossella ;

Dall'Ara, Francesca ;

Franceschini, Franco ;

Tincani, Angela .

CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (07)

[3] Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives [J].

Cavalli, Eugenio ;

Bramanti, Alessia ;

Ciurleo, Rosella ;

Tchorbanov, Andrey, I ;

Giordano, Antonio ;

Fagone, Paolo ;

Belizna, Cristina ;

Bramanti, Placido ;

Shoenfeld, Yehuda ;

Nicoletti, Ferdinando .

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2020, 46 (03) :903-912

[4] Cytokines and thrombosis [J].

Dosquet, C ;

Weill, D ;

Wautier, JL .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 25 :S13-S19

[5] Thrombosis as an intravascular effector of innate immunity [J].

Engelmann, Bernd ;

Massberg, Steffen .

NATURE REVIEWS IMMUNOLOGY, 2013, 13 (01) :34-45

[6] Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry [J].

Gianfrancesco, Milena ;

Hyrich, Kimme L. ;

Al-Adely, Sarah ;

Carmona, Loreto ;

Danila, Maria, I ;

Gossec, Laure ;

Izadi, Zara ;

Jacobsohn, Lindsay ;

Katz, Patricia ;

Lawson-Tovey, Saskia ;

Mateus, Elsa F. ;

Rush, Stephanie ;

Schmajuk, Gabriela ;

Simard, Julia ;

Strangfeld, Anja ;

Trupin, Laura ;

Wysham, Katherine D. ;

Bhana, Suleman ;

Costello, Wendy ;

Grainger, Rebecca ;

Hausmann, Jonathan S. ;

Liew, Jean W. ;

Sirotich, Emily ;

Sufka, Paul ;

Wallace, Zachary S. ;

Yazdany, Jinoos ;

Machado, Pedro M. ;

Robinson, Philip C. .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (07) :859-866

[7] Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice [J].

Glass, WG ;

Subbarao, K ;

Murphy, B ;

Murphy, PM .

JOURNAL OF IMMUNOLOGY, 2004, 173 (06) :4030-4039

[8] Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis [J].

Gralinski, Lisa E. ;

Sheahan, Timothy P. ;

Morrison, Thomas E. ;

Menachery, Vineet D. ;

Jensen, Kara ;

Leist, Sarah R. ;

Whitmore, Alan ;

Heise, Mark T. ;

Baric, Ralph S. .

MBIO, 2018, 9 (05)

[9] Prominent changes in blood coagulation of patients with SARS-CoV-2 infection [J].

Han, Huan ;

Yang, Lan ;

Liu, Rui ;

Liu, Fang ;

Wu, Kai-lang ;

Li, Jie ;

Liu, Xing-hui ;

Zhu, Cheng-liang .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (07) :1116-1120

[10] Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J].

Huang, Chaolin ;

Wang, Yeming ;

Li, Xingwang ;

Ren, Lili ;

Zhao, Jianping ;

Hu, Yi ;

Zhang, Li ;

Fan, Guohui ;

Xu, Jiuyang ;

Gu, Xiaoying ;

Cheng, Zhenshun ;

Yu, Ting ;

Xia, Jiaan ;

Wei, Yuan ;

Wu, Wenjuan ;

Xie, Xuelei ;

Yin, Wen ;

Li, Hui ;

Liu, Min ;

Xiao, Yan ;

Gao, Hong ;

Guo, Li ;

Xie, Jungang ;

Wang, Guangfa ;

Jiang, Rongmeng ;

Gao, Zhancheng ;

Jin, Qi ;

Wang, Jianwei ;

Cao, Bin .

LANCET, 2020, 395 (10223) :497-506

← 1 2 3 4 →